In a patient with an EGFR exon 20 insertion mutation with stage IIIA lung adenocarcinoma, is there any experience using amivantamab + carboplatin + pemetrexed in a neoadjuvant fashion?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · UT Health San Antonio
Answered on
No. What is interesting is the use of not a chemoimmunotherapy neoadjuvant approach vs upfront surgery, since more likely than not, the EGFR exon 20 mutation offsets ICI efficacy.
Join for free or sign in to see the full answer